miRNAs as Potential Biomarkers for Traumatic Brain Injury: Pathway From Diagnosis to Neurorehabilitation.
miRNAs as Potential Biomarkers for Traumatic Brain Injury: Pathway From Diagnosis to Neurorehabilitation.
复制标题
DOI：
10.1097/htr.0000000000000632
复制
发表时间：
2020-11
影响因子：
2.4
通讯作者：
A. Herrold;S. Kletzel;Eileen M. Foecking;K. Saban;Magdalena M. Przybycien-Szymanska;M. Zilliox;D. Bhaumik;Dustin Lange;J. Radke;I. Salinas;Theresa L Bender Pape
中科院分区：
文献类型：
--
作者：
A. Herrold;S. Kletzel;Eileen M. Foecking;K. Saban;Magdalena M. Przybycien-Szymanska;M. Zilliox;D. Bhaumik;Dustin Lange;J. Radke;I. Salinas;Theresa L Bender Pape
需要能够促进创伤性脑损伤（TBI）的精确神经康复的生物标志物。microRNA（miRNAs）具有生物学特性，可以使它们非常适合在鉴别诊断和诊断中发挥关键作用，并告知对特定治疗的反应可能性。目的回顾脑外伤后miRNA改变的证据，并评估与脑外伤特异性miRNA潜在神经康复应用相关的科学现状。本范围综述包括57项评估TBI后miRNA的动物和人体研究。使用PubMed、Scopus和Google Scholar搜索引擎。结果提出了miRNA生物标志物评估的金标准分析步骤。已发表的研究评价了miRNA作为TBI诊断、严重程度、自然恢复和治疗诱导结局的潜在生物标志物的证据，包括统计学评价。越来越多的证据表明，特定的miRNAs，包括miR 21，作为TBI生物标志物。结论：有证据表明，在人类和动物模型中TBI中存在差异miRNA表达;然而，需要使用严格的标准化方法来填补复制方面的空白，以分离出一组一致的miRNA变化。需要对TBI进行纵向研究，以了解miRNA如何在临床实践中作为生物标志物。
BACKGROUND Biomarkers that can advance precision neurorehabilitation of the traumatic brain injury (TBI) are needed. MicroRNAs (miRNAs) have biological properties that could make them well suited for playing key roles in differential diagnoses and prognoses and informing likelihood of responsiveness to specific treatments. OBJECTIVE To review the evidence of miRNA alterations after TBI and evaluate the state of science relative to potential neurorehabilitation applications of TBI-specific miRNAs. METHODS This scoping review includes 57 animal and human studies evaluating miRNAs after TBI. PubMed, Scopus, and Google Scholar search engines were used. RESULTS Gold standard analytic steps for miRNA biomarker assessment are presented. Published studies evaluating the evidence for miRNAs as potential biomarkers for TBI diagnosis, severity, natural recovery, and treatment-induced outcomes were reviewed including statistical evaluation. Growing evidence for specific miRNAs, including miR21, as TBI biomarkers is presented. CONCLUSIONS There is evidence of differential miRNA expression in TBI in both human and animal models; however, gaps need to be filled in terms of replication using rigorous, standardized methods to isolate a consistent set of miRNA changes. Longitudinal studies in TBI are needed to understand how miRNAs could be implemented as biomarkers in clinical practice.